Mylan, assailed for hefty price increases on its lifesaving EpiPen, had the second-highest executive pay among all U.S. drug and biotech firms over the past five years, paying its top five managers a total of nearly $300 million.
from WSJ.com: US Business http://ift.tt/2cXevU7
via IFTTT
No comments:
Post a Comment